Propafenone for Supraventricular Tachyarrhythmias
Propafenone is indicated for preventing recurrence of symptomatic paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardia in patients without structural heart disease, with typical dosing of 450-900 mg daily in divided doses. 1
Indications
Propafenone is a Class IC antiarrhythmic agent with three FDA-approved indications 1:
- Paroxysmal atrial fibrillation/flutter (PAF) with disabling symptoms - to prolong time to recurrence
- Paroxysmal supraventricular tachycardia (PSVT) with disabling symptoms - to prolong time to recurrence
- Life-threatening ventricular arrhythmias (sustained ventricular tachycardia) - hospital initiation required
Critical limitation: Propafenone should NOT be used for chronic atrial fibrillation or for rate control during atrial fibrillation 1. It has not been shown to enhance survival in patients with arrhythmias 1.
Dosing Regimens
Acute Cardioversion of Recent-Onset AF
Oral loading: 600 mg single dose achieves cardioversion in 56-83% of patients within 2-6 hours 2, 3. The effect occurs between 2-6 hours after oral administration 4.
Intravenous: 1.5-2.0 mg/kg over 10-20 minutes produces earlier conversion than oral dosing 2. IV propafenone results in fewer conversions in the first 2 hours compared to oral, but similar rates by 6-8 hours 2.
Long-Term Maintenance Therapy
Standard dosing: 450-900 mg daily in divided doses 2
Specific regimens 3:
- 300 mg twice daily - effective and well-tolerated first-line dose 5
- 300 mg three times daily - more effective but associated with more frequent side effects 3, 5
Sustained-release formulation: 225-425 mg twice daily delays symptomatic recurrence and reduces ventricular rate at relapse 3.
The UK PSVT study demonstrated that 300 mg BID had a relative risk reduction of 6.8 for PSVT and 6.0 for PAF compared to placebo 5. The 300 mg TID dose showed even greater efficacy when adverse events were excluded (relative risk 15.0 for PSVT) but caused more side effects 5.
Absolute Contraindications
Propafenone must be avoided in 4, 2, 4, 3, 6:
- Ischemic heart disease or coronary artery disease - high risk for proarrhythmic effects
- Heart failure or left ventricular dysfunction - negative inotropic effects can precipitate decompensation
- Severe obstructive lung disease - weak beta-blocking properties can cause bronchospasm
- Severe left ventricular hypertrophy - increased proarrhythmic risk
- Sinus node dysfunction or AV conduction disturbances (unless pacemaker present) 6
- Prolonged QTc >500 ms 6
The 2024 ESC guidelines explicitly state that flecainide or propafenone is recommended "excluding those with impaired left ventricular systolic function, severe left ventricular hypertrophy, or coronary artery disease" 6.
Monitoring Requirements
Pre-Treatment Assessment
- Baseline ECG - document PR interval, QRS duration, QTc 1
- Echocardiography - exclude structural heart disease, assess LV function
- Electrolyte levels - particularly potassium and magnesium 4
During Initiation
Hospital monitoring is required for initiation in patients with life-threatening ventricular arrhythmias 1. For supraventricular arrhythmias in appropriately selected patients without structural heart disease, outpatient initiation may be considered, though safety data are limited 7.
On-Going Monitoring
Regular ECG monitoring is essential 8:
- QRS duration increase ≥25% from baseline signals potential proarrhythmic risk - reduce dose or discontinue 8
- Monitor PR interval prolongation (mean increase 17.8-21.9% at 900 mg/day) 1
- QRS duration increases dose-dependently (mean 6.4-17.3% increase) 1
Close follow-up is necessary to detect development of ischemia or heart failure 3.
Adverse Effects and Proarrhythmia
Common Adverse Effects
Dose-dependent and more frequent with structural heart disease 9:
- Rapid atrial flutter with 1:1 AV conduction - potentially life-threatening complication 4, 2, 4
- Ventricular tachycardia
- Intraventricular conduction disturbances
- Hypotension and bradycardia at conversion 4
Critical caveat: Concomitant AV nodal blocking agents (beta-blockers, diltiazem, or verapamil) are recommended to prevent rapid ventricular response if atrial flutter develops 1, 10.
Proarrhythmic Risk
The incidence of atrial flutter with 1:1 response is approximately 3.5-5% overall 7, but only 0.3% (2/709 patients) developed hemodynamically significant 1:1 conduction in pooled studies 7. However, this risk mandates careful patient selection and monitoring.
Clinical Efficacy Data
Acute cardioversion: Success rates of 72-78% within 8 hours with oral loading (450-600 mg) in hospitalized patients with recent-onset AF 7.
Long-term maintenance: The UK PSVT study showed propafenone 300 mg BID reduced treatment failure risk by 85% (relative risk 6.8) for PSVT and 83% (relative risk 6.0) for PAF compared to placebo 5. Propafenone reduced days in AF from 51% to 27% compared to placebo 3.
Comparative effectiveness: Propafenone was equally effective as sotalol (30% vs 37% in sinus rhythm at 12 months) 3 and superior to quinidine with fewer side effects 3. However, amiodarone was more effective than propafenone in the CTAF study 3.
Special Populations
Focal atrial tachycardia: Propafenone can be effective for ongoing management in patients without structural heart disease (Class IIa recommendation) 10. Small case series show focal AT suppression in most patients 10.
Pregnancy: Propafenone is no longer recommended during pregnancy per 2020 ESC guidelines 11.
Hepatic dysfunction: Clearance is reduced and elimination half-life increased; bioavailability can reach 60-70% (versus 3-21% normally) 1. Dose adjustment required.
Pharmacokinetics Relevant to Clinical Use
- Peak levels: 3.5 hours after oral administration 1
- Therapeutic range: 0.2-1.5 µg/mL 1
- Nonlinear kinetics: Three-fold dose increase (300 to 900 mg/day) produces ten-fold increase in steady-state concentration 1
- Elimination half-life: 2-10 hours in >90% of patients (rapid metabolizers) 1
- Food effect: Increases peak level but does not significantly change bioavailability during chronic dosing 1